NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=179561&from=4CLASS PERIOD: January 8, 2024 to Septembe ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the failure of a key study [1][2]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements while concealing material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [1]. - The EFZO-FIT study did not meet its primary endpoint, which was announced on September 15, 2025, leading to a drastic stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [1]. - The company plans to engage with the FDA to determine the next steps following the disappointing study results [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline of December 8, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit due to alleged misleading statements and operational deficiencies related to the company's infant formula business [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 27, 2023, to November 4, 2025, Perrigo made materially false and misleading statements [3]. - Specific allegations include significant underinvestment in the infant formula business acquired from Nestlé, necessitating substantial capital and operational expenditures beyond stated estimates [3]. - The complaint also highlights significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [3]. Group 2: Class Action Details - Shareholders who purchased PRGO shares during the specified class period are encouraged to register for the class action, with a deadline of January 16, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflate stock prices [5].

LOS ANGELES, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against CarMax, Inc. (“CarMax” or “the Company”) (NYSE: KMX) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of KMX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff ...

Accessibility StatementSkip Navigation LOS ANGELES, Dec. 1, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  Primo Brands Corporation ("Primo " or "the Company") (NYSE: PRMB ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of PRMB during the class period listed are encouraged to contact the firm regarding possible le ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the efficacy of its drug nimacimab [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye made false and misleading statements regarding the efficacy of nimacimab, which did not demonstrate the claimed effectiveness [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for alleged violations of securities laws, specifically for making false and misleading statements regarding enrollment figures and compliance practices [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from October 22, 2024, to October 28, 2025, with a deadline for lead plaintiff appointments set for January 12, 2026 [2]. - The complaint alleges that Stride misrepresented enrollment figures by including "ghost students" and failed to conduct necessary background checks and compliance requirements, leading to materially misleading public statements [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential participation in the lawsuit, with no cost or obligation to join [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for alleged violations of securities laws, specifically for making false and misleading statements regarding its development tenant pipeline [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from January 27, 2025, to October 27, 2025, with a deadline for lead plaintiff appointments set for January 26, 2026 [2]. - The complaint alleges that Alexandria made false claims about its positive comments on its development tenant pipeline, which were not based on factual information, rendering its public statements materially misleading [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: DJS Law Group Overview - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit for alleged violations of federal securities laws, with claims that the company made false and misleading statements regarding its business operations and the demand for its products [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is defined as from August 7, 2025, to September 29, 2025, during which shareholders are encouraged to contact the DJS Law Group for potential lead plaintiff appointments [2]. - The lawsuit alleges that Firefly exaggerated the demand for its Spacecraft Solutions division and misled investors about the commercial potential of the Alpha rocket, resulting in materially misleading public statements throughout the class period [3]. Next Steps for Shareholders - Shareholders who purchased shares of Firefly during the specified timeframe can register to participate in the case, which includes enrollment in a portfolio monitoring software for status updates [4]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy and legal support [5].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the efficacy of its product, nimacimab [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye's public statements were materially misleading, as the company failed to demonstrate the efficacy of nimacimab as previously claimed [2]. Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group to participate in the lawsuit [3]. - There is no cost or obligation for shareholders to enroll in the case, and they will receive updates through a portfolio monitoring software [3]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].